Compare JFR & ATTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFR | ATTO |
|---|---|---|
| Founded | 2004 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2004 | 2026 |
| Metric | JFR | ATTO |
|---|---|---|
| Price | $7.05 | $15.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.20 |
| AVG Volume (30 Days) | ★ 745.2K | 225.9K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.06 | $12.94 |
| 52 Week High | $8.00 | $28.00 |
| Indicator | JFR | ATTO |
|---|---|---|
| Relative Strength Index (RSI) | 36.91 | 44.83 |
| Support Level | N/A | $13.52 |
| Resistance Level | $7.64 | $17.10 |
| Average True Range (ATR) | 0.09 | 1.39 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 2.86 | 28.75 |
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests the majority of its managed assets in secured senior loans and unsecured senior loans, which unsecured senior Loans are generally, at the time of investment, investment grade quality.
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.